<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209793</url>
  </required_header>
  <id_info>
    <org_study_id>R846-HV-1007</org_study_id>
    <nct_id>NCT01209793</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety and Tolerability of Intravenously Administered REGN846 (SAR302352) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the safety and tolerability of a single ascending&#xD;
      intravenous (IV) dose of REGN846 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Baseline through end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile</measure>
    <time_frame>Baseline through end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Visits 2, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(3:1, active: placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(3:1, active: placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(3:1, active: placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(3:1, active: placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(3:1, active: placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REGN846</intervention_name>
    <description>5 IV cohorts (Dose 1, 2, 3, 4, 5)</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_label>Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women between the ages of 18 and 65; women must be postmenopausal or&#xD;
             surgically sterile&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, inclusive&#xD;
&#xD;
          -  Normal vital signs after resting in a sitting position for 5 minutes:&#xD;
&#xD;
          -  Normal standard 12-lead ECG&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          -  Provide signed informed consent&#xD;
&#xD;
          -  Able to understand and complete study-related questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or prior history of smoking&#xD;
&#xD;
          -  Any illness or condition that would adversely affect the subject's participation in&#xD;
             this study&#xD;
&#xD;
          -  Hospitalization within 60 days of the screening visit&#xD;
&#xD;
          -  Any clinically significant abnormalities observed during the screening visit&#xD;
&#xD;
          -  History of or positive human immunodeficiency virus (HIV) screen result at the&#xD;
             screening visit&#xD;
&#xD;
          -  History of positive blood test for hepatitis B/hepatitis C or positive hepatitis&#xD;
             screen result at the screening visit&#xD;
&#xD;
          -  History of positive drug screen result for drug or alcohol abuse within a year prior&#xD;
             to the screening visit&#xD;
&#xD;
          -  Known sensitivity to any of the components of the Investigational Product formulation&#xD;
&#xD;
          -  Participation in any clinical research study evaluating another investigational drug&#xD;
             or therapy within 30 days or at least 5 half-lives (whichever is longer), of the&#xD;
             investigational drug prior to the screening visit&#xD;
&#xD;
          -  Any condition that would place the subject at risk, interfere with participation in&#xD;
             the study&#xD;
&#xD;
          -  History of a parasitic infection or recent (within the previous 6 months) travel to a&#xD;
             parasitic endemic area&#xD;
&#xD;
          -  Live/attenuated vaccinations within 12 weeks of screening or during the study&#xD;
&#xD;
          -  Any subjects with planned elective surgery&#xD;
&#xD;
          -  Sexually active men who are unwilling to utilize adequate contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

